The results of two clinical trials—led by the Upstream Lab at St. Michael’s Hospital in Toronto and Oxford University, published in the New England Journal of Medicine—provide new evidence to consider when funding, prescribing, or taking Paxlovid to treat COVID-19.
This article was originally published on MedicalXpress.com

